In conclusion, this study demonstrates that targeting the NLRP3 inflammasome is beneficial to improve NASH symptoms such as inflammation, lipid accumulation, and fibrosis. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.